Exagen Inc. Reports Strong Q4 and Full-Year 2025 Financial Results, Provides 2026 Outlook

Key Highlights from the Report

• Quarterly Revenue: \$16.6 million for Q4 2025
• Full-Year Revenue: \$66.6 million for the year ended December 31, 2025
• Gross Margin: 55.4% reported for the year
• Net Loss: \$(15.1) million for full-year 2025, \$(0.20) per share in Q4 2025
• Cash Position: \$32.4 million in cash, cash equivalents, and restricted cash at year-end
• Balance Sheet Strengthened: Completed \$20 million public offering and secured a \$25 million credit facility
• 2026 Revenue Guidance: Expects \$70 million to \$73 million for full-year 2026

Detailed Financial Review

Exagen Inc. (Nasdaq: XGN) delivered a strong performance in the fourth quarter and full year of 2025, with significant developments that could impact the company’s future trajectory and share price.

Revenue and Profitability

• Revenue for Q4 2025: \$16.6 million, up from \$14.9 million in the same quarter of 2024, indicating continued growth in test adoption and commercial execution.
• Full-year Revenue: \$66.6 million, a substantial increase from \$55.6 million in 2024.
• Gross Margin: 55.4% for the year, reflecting operational efficiency in delivering testing solutions.
• Net Loss: \$(15.1) million for the year, or \$(0.83) per share, a decrease from the prior year’s \$(15.8) million loss, indicating improved cost control.

Liquidity and Capital Structure

• Cash Position: Exagen ended 2025 with \$32.4 million in cash, cash equivalents, and restricted cash, providing a solid liquidity buffer.
• Balance Sheet Actions: The company completed a \$20 million public offering and secured a new \$25 million credit facility during the year, positioning the balance sheet to support its path to cash flow positivity.
• Borrowings: Borrowings were reported at \$643,000 (current) and \$13.5 million (non-current) at year-end.

Operating Expenses

• Selling, General & Administrative (SG&A): \$41.4 million for the year, up from \$34.4 million in 2024, reflecting investments in commercial operations.
• Research & Development (R&D): \$1.8 million, relatively stable compared to the prior year.

Non-GAAP Results

Exagen reported Adjusted EBITDA (non-GAAP) of \$(4.3) million for the year, showing improvement from \$(6.9) million in 2024. Management highlighted Adjusted EBITDA as a key measure of operational performance, excluding interest, taxes, depreciation, amortization, stock-based compensation, and certain other items.

2026 Financial Outlook

The company provided full-year 2026 revenue guidance in the range of \$70 million to \$73 million, representing continued top-line growth expectations.

Strategic and Shareholder Updates

• Positioned for Cash Flow Positivity: Management emphasized the strengthened balance sheet and operational improvements as positioning the company on its path to cash flow positivity.
• Ongoing Investments: Continuous investment in commercial infrastructure and pipeline development to drive long-term growth.
• Conference Call: Exagen will hold a conference call to discuss results and outlook, with a replay available for investors.

Potential Price-Sensitive Information for Shareholders

• Revenue Growth and Future Guidance: The strong revenue growth in 2025 and the bullish guidance for 2026 could positively influence investor sentiment and share price.
• Strengthened Balance Sheet: The successful capital raise and new credit facility reduce financial risk and support future expansion, potentially appealing to risk-conscious investors.
• Path to Cash Flow Positivity: Management’s stated goal of achieving cash flow positivity, backed by increased liquidity, is a key milestone that could be a significant catalyst for the stock.
• Gross Margin Improvement: Sustained gross margin above 55% reflects operational scalability, which can drive future profitability.
• Non-GAAP Improvements: Progress in reducing Adjusted EBITDA losses demonstrates improving core business health.

Risks and Forward-Looking Statements

Management cautioned that forward-looking statements are subject to risks, including delays in reimbursement and regulatory decisions, the effects of inflation and tariffs, execution of business strategies, and the ability to achieve significant market acceptance and funding. These factors could affect actual results versus expectations.

Conclusion

Exagen Inc.’s strong revenue growth, improved margins, enhanced cash position, and optimistic 2026 outlook represent potentially price-sensitive developments. Investors should monitor the company’s progress towards cash flow positivity and continued execution on commercial and operational fronts, as these could drive future share price performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. All forward-looking statements are subject to risks and uncertainties as outlined in Exagen Inc.’s SEC filings. Investors should perform their own due diligence and consult a professional advisor before making investment decisions.

View EXAGEN INC. Historical chart here